Skip to Content

Late in 2005 the Food and Drug Administration approved ­Celgene’s Revlimid. The drug brought in $321 million in sales its first full year on the market. A decade later it collected a cool $6.97 billion (more than 60% of the biotech’s 2016 revenues), and sales are expected to cross the $8 billion mark this year. Celgene has ridden Revlimid’s success and approvals for various diseases to a 270% gain in market value in 10 years. Now analysts are bullish on the com­pany’s experimental treatments for multiple sclerosis, ulcerative colitis, and Crohn’s disease.

Company Information

Overall Score1.7
Health Care
Mark J. Alles
HQ Location
Summit, N.J.
Revenues ($M) (Past 12 Months)$12,191
Profits ($M) (Past 12 Months)$2,602
Market Value as of Oct. 9, 2017 ($M)$108,958